Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Common Equity (2016 - 2025)

Iovance Biotherapeutics has reported Common Equity over the past 13 years, most recently at $698.6 million for Q4 2025.

  • Quarterly results put Common Equity at $698.6 million for Q4 2025, down 1.66% from a year ago — trailing twelve months through Dec 2025 was $698.6 million (down 1.66% YoY), and the annual figure for FY2025 was $698.6 million, down 1.66%.
  • Common Equity for Q4 2025 was $698.6 million at Iovance Biotherapeutics, down from $702.3 million in the prior quarter.
  • Over the last five years, Common Equity for IOVA hit a ceiling of $773.5 million in Q3 2024 and a floor of $578.6 million in Q2 2023.
  • Median Common Equity over the past 3 years was $698.5 million (2025), compared with a mean of $692.0 million.
  • Biggest five-year swings in Common Equity: soared 32.83% in 2024 and later fell 9.2% in 2025.
  • Iovance Biotherapeutics' Common Equity stood at $584.6 million in 2023, then increased by 21.52% to $710.4 million in 2024, then dropped by 1.66% to $698.6 million in 2025.
  • The last three reported values for Common Equity were $698.6 million (Q4 2025), $702.3 million (Q3 2025), and $698.5 million (Q2 2025) per Business Quant data.